Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2025-12-25 @ 10:48 PM
Study NCT ID:
NCT05491967
Status:
COMPLETED
Last Update Posted:
2025-09-08
First Post:
2022-07-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Comparison of Vascular Risk in Patients Treated for Obstructive Sleep Apnea/Hypopnea Syndrome
Sponsor:
Centre Hospitalier de Valence
Organization:
Study Overview
Official Title:
Comparison of Vascular Risk in Patients Treated for Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) With Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Orthosis
Status:
COMPLETED
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SAHOSVAS
Brief Summary:
a monocentric,non interventional, prospective study to compare cardiovascular risk in patients with Obstructive Sleep Apnea/Hypopnea Syndrome treated with Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Orthosis.
Detailed Description:
The first-line treatment of severe Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) is nocturnal ventilation with Continuous Positive Airway Pressure (CPAP). and The second-line treatment is the mandibular advancement orthosis (MAO)\].
CPAP is the most effective treatment to reduce the apnea-hypopnea index (AHI). However, its tolerance is sometimes difficult, causing many discontinuations.
The purpose of this review is to evaluate a vascular morbimortality criteria:
* Cardiovascular: myocardial infarction, heart failure, rhythm disorder
* Neurological: transient or non transient stroke
* ophthalmologic: anterior ischemic optic neuropathy, occlusion of the central artery or central retinal vein occlusion
CPAP is the most effective treatment to reduce the apnea-hypopnea index (AHI). However, its tolerance is sometimes difficult, causing many discontinuations.
The purpose of this review is to evaluate a vascular morbimortality criteria:
* Cardiovascular: myocardial infarction, heart failure, rhythm disorder
* Neurological: transient or non transient stroke
* ophthalmologic: anterior ischemic optic neuropathy, occlusion of the central artery or central retinal vein occlusion
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: